Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 122, Issue 3, 2011, Pages 495-500

  Santin, Alessandro D ^a   Sill, Michael W ^b,c   McMeekin, D Scott ^d   Leitao Jr , Mario M ^e   Brown, Jubilee ^f   Sutton, Gregory P ^g   Van Le, Linda ^h   Griffin, Patricia ⁱ   Boardman, Cecelia H ^j  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g ST VINCENT HOSPITAL   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ Upstate Carolina CCOP   (United States)

^j VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

more..

Author keywords

Cervical neoplasms; Cetuximab; EGFR; Immunotherapy

Indexed keywords

CETUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; LEUKOPENIA; LUNG DISEASE; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 80051551247     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.05.040     Document Type: Article

References (58)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. F. Landoni, A. Maneo, A. Colombo, F. Placa, R. Milani, and P. Perego Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer Lancet 350 1997 535 540 (Pubitemid 27348428)
3. C.L. Arteaga Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol 29 2002 3 9 (Pubitemid 35191041)
4. J. Baselga New therapeutic agents targeting the epidermal growth factor receptor J Clin Oncol 18 2000 54S 59S
5. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 2000 15 23 discussion, 41-42
6. J. Baselga Targeting the epidermal growth factor receptor: a clinical reality J Clin Oncol 19 2001 41S 44S (Pubitemid 32880078)
7. P.J. O'Dwyer, and A.B. Benson III Epidermal growth factor receptor-targeted therapy in colorectal cancer Semin Oncol 29 Suppl. 14 2002 10 11
8. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565 (Pubitemid 32197693)
9. J. Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672 (Pubitemid 35283957)
10. Y. Sako, S. Minoghchi, and T. Yanagida Single-molecule imaging of EGFR signaling on the surface of living cells Nat Cell Biol 2 2000 168 172
11. J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 103 2000 211 225
12. M.A. Olayioye, I. Beuvink, K. Horsch, J.M. Daly, and N.E. Hynes ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases J Biol Chem 274 1999 17209 17218
13. H. Kim, and W.J. Muller The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis Exp Cell Res 253 1999 78 87
14. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
15. J. Mendelsohn, and Z. Fan Epidermal growth factor receptor family and chemosensitization J Natl Cancer Inst 89 1997 341 343 (Pubitemid 27102599)
16. R. Corvo, P. Antognoni, and G. Sanguineti Biological predictors of response to radiotherapy in head and neck cancer: recent advances and emerging perspectives Tumori 87 2001 355 363
17. A.M. Kersemaekers, G.J. Fleuren, G.G. Kenter, L.J. Van den Broek, S.M. Uljee, and J. Hermans Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis Clin Cancer Res 5 1999 577 586 (Pubitemid 29131967)
18. G.E. Kim, Y.B. Kim, N.H. Cho, H.C. Chung, H.R. Pyo, and J.D. Lee Synchronous co-expression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival Clin Cancer Res 10 2004 1366 1374 (Pubitemid 38365230)
19. J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, and M. Bos Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 2000 904-4
20. F. Ciardiello, V. Damiano, R. Bianco, C. Bianco, G. Fontanini, and M. De Laurentiis Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A J Natl Cancer Inst 88 1996 1770 1776 (Pubitemid 26405015)
21. T. Kawamoto, J.D. Sato, A. Le, J. Polikoff, G.H. Sato, and J. Mendelsohn Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody Proc Natl Acad Sci U S A 80 1983 1337 1341 (Pubitemid 13082800)
22. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, and G.H. Sato Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 1983 511 529
23. Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells J Biol Chem 269 1994 27595 27602 (Pubitemid 24346592)
24. X. Wu, M. Rubin, Z. Fan, T. DeBlasio, T. Soos, and A. Koff Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody Oncogene 12 1996 1397 1403
25. M. Mandal, L. Adam, J. Mendelsohn, and R. Kumar Nuclear targeting of Bax during apoptosis in human colorectal cancer cells Oncogene 17 1998 999 1007 (Pubitemid 28425410)
26. A.M. Petit, J. Rak, M.C. Hung, P. Rockwell, N. Goldstein, and B. Fendly Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1997 1523 1530 (Pubitemid 27527914)
27. T. Matsumoto, P. Perrotte, and M. Bar-Eli Blockade of EGF-R signalling with anti-EGFR monoclonal antibody (Mb) C225 inhibits matrix metalloproteinase-9 (MMP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo Proc Am Assoc Cancer Res 39 83 1998 (Abs)
28. J. Baselga, L. Norton, H. Masui, A. Pandiella, K. Coplan, and W.H. Miller Jr. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J Natl Cancer Inst 85 1993 1327 1333 (Pubitemid 23249725)
29. L. Milas, K. Mason, N. Hunter, S. Petersen, M. Yamakawwa, and K. Ang In vivo enhancement of tumor radio response by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708 (Pubitemid 30111496)
30. M.C. Prewett, A.T. Hooper, R. Bassi, L.M. Ellis, H.W. Waksal, and D.J. Hicklin Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin Cancer Res 8 2002 994 1003 (Pubitemid 34517632)
31. L.B. Saltz, N.J. Meropol, P.J. Loehrer, M.N. Needle, J. Kopit, and R.J. Mayer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208 (Pubitemid 41079832)
32. D.M. Shin, N.J. Donato, R. Perez-Soler, H.J. Shin, J.Y. Wu, and P. Zhang Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213 (Pubitemid 32708671)
33. M.W. Sill, and G. Yothers A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials Technical report 2006 State University of New York at Buffalo Buffalo
34. D.R. Cox Regression models and life tables J R Stat Soc Ser B 34 1972 187 220
35. K.S. Tewari, and B.J. Monk Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer Curr Oncol Rep 7 2005 419 434 (Pubitemid 41684228)
36. H.J. Long III, B.N. Bundy, E.C. Grendys, J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 2005 4626 4633 (Pubitemid 46224065)
37. F. Robert, M.P. Ezekiel, S.A. Spencer, R.F. Meredith, J.A. Bonner, and M.B. Khazaeli Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 3234 3243 (Pubitemid 32591441)
38. J. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578 (Pubitemid 43209104)
39. J. Baselga, J. Trigo, and J. Bourhis Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen Proc Am Soc Clin Oncol 21 2002 226a (Abstract 900)
40. J.B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, and F. Rolland Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177 (Pubitemid 46954639)
41. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, and A. Tse Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803
42. M.G. Noordhuis, J.J. Eijsink, K.A. Ten Hoor, F. Roossink, H. Hollema, and H.J. Arts Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer Clin Cancer Res 15 2009 7389 7397
43. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, and P. Kosmidis Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
44. E. Massarelli, M. Varella-Garcia, X. Tang, A.C. Xavier, N.C. Ozburn, and D.D. Liu KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896 (Pubitemid 46849563)
45. F.R. Hirsch, R.S. Herbst, C. Olsen, K. Chansky, J. Crowley, and K. Kelly Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy J Clin Oncol 26 2008 3351 3357
46. H. Arias-Pulido, N. Joste, A. Chavez, C.Y. Muller, D. Dai, and H.O. Smith Absence of epidermal growth factor receptor mutations in cervical cancer Int J Gynecol Cancer 18 2008 749 754 (Pubitemid 352020185)
47. R. Marzano, G. Corrado, R. Merola, C. Sbiroli, F. Guadagni, and E. Vizza Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression Eur J Cancer 40 2004 1624 1629 (Pubitemid 38757754)
48. A. Stenzel, A. Semczuk, K. Rozynskal, J. Jakowicki, and J. Wojcierowski "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases Pathol Res Pract 197 2001 597 603 (Pubitemid 32834399)
49. T. Pochylski, and A. Kwasniewska Absence of point mutation in codons 12 and 13 of K-RAS oncogenein HPV-associated high grade dysplasia and squamous cell cervical carcinoma Eur J Obstet Gynecol Reprod Biol 111 2003 68 73 (Pubitemid 37235950)
50. S. Kang, H.S. Kim, S.S. Seo, S.Y. Park, D. Sidransky, and S.M. Dong Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma Gynecol Oncol 105 2007 662 666 (Pubitemid 46734191)
51. K.I. Pappa, M. Choleza, S. Markaki, E. Giannikaki, A. Kyroudi, and G. Vlachos Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status Gynecol Oncol 100 2006 596 600 (Pubitemid 43246877)
52. J.H. Farley, and K.E. Oliver Cisplatin plus Cetuximab in the treatment of recurrent and persistent cancers of the cervix US Oncol Rev 6 2010 45 49
53. Z. Fan, H. Masui, I. Altas, and J. Mendelsohn Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res 53 1993 4322 4328 (Pubitemid 24146785)
54. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 2000 443 446 (Pubitemid 30208162)
55. S. Bellone, G. Frera, G. Landolfi, C. Romani, E. Bandiera, and G. Tognon Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecol Oncol 106 2007 513 520 (Pubitemid 47302461)
56. A. Fiander, M. Adams, A.S. Evans, A.J. Bennett, and L.K. Borysiewicz Immunocompetent for immunotherapy? A study of the immunocompetence of cervical cancer patients Int J Gynecol Oncol 5 1995 438 442
57. A.D. Santin, P.L. Hermonat, A. Ravaggi, S. Bellone, J. Roman, and S. Pecorelli Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix Int J Radiat Oncol Biol Phys 48 2000 997 1006
58. A.D. Santin, S. Bellone, M. Palmieri, B. Bossini, D. Dunn, and J.J. Roman Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10 Int J Radiat Oncol Biol Phys 54 2002 1345 1355 (Pubitemid 35380034)